Medical Oncologist
CION Cancer Clinics
Durvalumab plus tremelimumab for liver cancer: who it is for | CION Cancer Clinics
Durvalumab plus tremelimumab is a pair of immunotherapy drugs for primary liver cancer that cannot be removed or treated locally. It is a first-choice option when the liver still works well, and it is especially useful when bleeding risk rules out bevacizumab. This page explains what the team checks, what happens once treatment starts, how it compares with the alternative and who it does not suit. At CION Cancer Clinics, a multidisciplinary tumour board weighs your liver function and your scans before recommending any treatment.
NG
Medically reviewed by Dr. Naresh GunduConsultant Medical Oncologist · MBBS, DNB (Internal Medicine), DM (Medical Oncology, AIIMS) · last reviewed October 2026, next review due October 2027
17+specialists on panel
15,000+patients treated
35+centres across Telangana & AP
4.8★ / 800+Google rating
On this page
- What is durvalumab plus tremelimumab, and who is it for?
- What does the team look at before suggesting it?
- What actually happens if you start this treatment?
- How does it compare with atezolizumab plus bevacizumab?
- Who does durvalumab plus tremelimumab not suit?
- What this page cannot tell you
- Common questions about durvalumab plus tremelimumab
The short answer
What is durvalumab plus tremelimumab, and who is it for?
Durvalumab plus tremelimumab is a pairing of two immunotherapy drugs for primary liver cancer (hepatocellular carcinoma, or HCC, the cancer that starts in the liver itself) that cannot be removed, burned away or treated through the blood vessels. It is one of the first drug treatments a team can offer when the liver is still working reasonably well. The large trial behind it was called HIMALAYA, which is the word most families see when they search.
Why it matters that there is no bevacizumab in it
The other common first choice, atezolizumab plus bevacizumab, includes a drug that raises the risk of bleeding. People with large swollen veins in the food pipe (varices), a recent bleed or certain heart and kidney problems may not be able to take it safely. Durvalumab plus tremelimumab uses two immune drugs instead, so it gives these people a strong first option.
Who this page is not about
This page is about cancer that started in the liver. If the cancer spread to the liver from the bowel, breast or elsewhere, the treatment follows the original cancer instead. Read about secondary cancer in the liver before reading further.
The choice between these two combinations is made on your liver, your veins and your other illnesses, not on which drug is newer.Before it is offered
What does the team look at before suggesting it?
The tumour board looks at three things together. A good answer on one does not make up for a bad answer on another.
The tumour
Drug treatment is used when the cancer is too large, too widespread, or has grown into the main vein of the liver, so that local treatments cannot control it on their own. The stage on the BCLC system, which links the tumour to liver function and fitness, guides this.
How well the liver works
The evidence comes mainly from people with Child-Pugh A liver function, the best-preserved group. With weaker function the benefit is far less certain and side effects weigh more heavily.
Blood tests that matter
- Bilirubin, the yellow pigment the liver clears
- Albumin, a protein the liver makes
- INR, a measure of how fast blood clots
Bleeding risk
If an endoscopy shows varices at high risk of bleeding, or there has been a recent bleed, the team will often lean towards this combination rather than one containing bevacizumab.
The immune system itself
Immune drugs can switch the body against its own organs. An active autoimmune illness, a past organ transplant or uncontrolled hepatitis B changes the safety picture and must be discussed first.
Not sure whether this applies to you?
Ask an oncologistFrom decision to first drip
What actually happens if you start this treatment?
Checks before the start
Blood tests for liver, kidney and thyroid function, a hepatitis B and C screen, and a recent scan to measure the tumour. If hepatitis B is active, antiviral tablets from a hepatologist usually start first.
The first visit
Both drugs are given as drips into a vein at the CION day-care unit. Tremelimumab is used only briefly, at the very start. Your oncologist will explain the timetable for your plan.
Durvalumab carries on alone
After the start, durvalumab continues on its own at regular visits, each with blood tests beforehand. Many people go home the same day and carry on with ordinary life between visits.
Scans to see whether it is working
Repeat scans are compared with the first one. A tumour that stays the same size can still count as the drug working. Read how response is assessed for what the report words mean.
Side by side
How does it compare with atezolizumab plus bevacizumab?
Durvalumab plus tremelimumab
Atezolizumab plus bevacizumab
Two immune drugs, no bleeding-risk drug
One immune drug plus a drug that cuts the tumour's blood supply
Often chosen when varices or bleeding are a worry
Usually needs an endoscopy and treated varices first
Immune side effects, such as rash, diarrhoea or liver inflammation, are the main concern
Adds blood pressure rise, protein in the urine and bleeding
Both have trial evidence over sorafenib
No trial has compared the two directly
Leave a number, we will call you
One field. No form to fill in, and no charge for the call.
Being honest
Who does durvalumab plus tremelimumab not suit?
It does not suit someone whose liver is failing. In Child-Pugh C liver function, with deep jaundice, fluid that keeps returning or repeated confusion, drug treatment for the cancer rarely helps and can harm. Comfort-focused care is often the kinder choice, and it is still active care.
Other reasons it may be ruled out
Anyone who has had a liver transplant is usually advised against immune drugs, because they can trigger rejection of the new liver. Read why immunotherapy is avoided after a transplant. A serious autoimmune illness, such as active lupus or inflammatory bowel disease, may flare. Someone who spends most of the day in bed is unlikely to gain enough to justify the visits and side effects.
When the tumour can still be treated locally
If the cancer is small enough to remove, burn or treat with TACE (medicine and blocking particles delivered through the liver's artery), those come first. Drug treatment is not a shortcut around a local treatment that could do more.
Immune side effects can appear months after a drip. Tell any doctor you see that you have had immunotherapy.What we cannot say here
What this page cannot tell you
It cannot tell you which combination is right for you. That depends on your scans, your endoscopy, your blood tests and your other illnesses, and it is decided by a medical oncologist who has seen all of them. It also cannot tell you how long the treatment will work or how long anyone will live. Trial results describe large groups, and no trial figure predicts one person.
Availability and cost
Durvalumab is sold in India. Tremelimumab has been harder to obtain, and supply can change. Ask your oncologist whether it can be arranged through regular supply right now. Costs vary with the plan and the hospital, so ask for a written, itemised estimate. The page on the monthly cost of each systemic option explains what moves the bill.
Where to go for the mechanics
How durvalumab works and its full side-effect list are covered on the durvalumab medicine page. This page is only about the decision.
Questions we are asked
Common questions about durvalumab plus tremelimumab
What was the HIMALAYA trial?
It was the large international study that tested durvalumab plus tremelimumab against sorafenib tablets in people with advanced primary liver cancer and well-preserved liver function. The combination did better than sorafenib overall. That result is why guidelines list it as a first-choice option today.
Is it better than atezolizumab plus bevacizumab?
Nobody knows for certain, because the two have never been tested head to head. Both beat sorafenib in their own trials. The choice usually comes down to bleeding risk, varices, blood pressure and kidney health, which is why your endoscopy and blood tests matter so much.
Can I have it if I have hepatitis B?
Usually yes, once the virus is controlled. Antiviral tablets are normally started first and continued throughout, under a hepatologist or physician. Hepatitis B is controlled, not removed, so do not stop those tablets on your own. See immunotherapy with hepatitis B or cirrhosis.
What side effects should we watch for at home?
Watch for loose motions that keep going, a new rash, yellow eyes, unusual tiredness, breathlessness or a cough that will not settle. These can be the immune system attacking healthy organs. Call your team the same day rather than waiting for the next visit, because early steroids work best.
Do I need to be admitted for each drip?
Usually not. Most people come in for the day, have their blood checked, receive the drip and go home. Families travelling from districts often plan the visit with one overnight stay in Hyderabad, but admission is not normally needed.
Can it be combined with TACE or radiation?
This is being studied, and some teams do combine them in selected people. It is not yet a routine standard. The tumour board will tell you whether a combination makes sense for your tumour. Read about TACE with systemic treatment.
What if it stops working?
There are further options. Tablets such as lenvatinib or sorafenib, and later regorafenib or cabozantinib, can be used if the liver is still working well enough. Your oncologist will review scans and liver tests before choosing the next step together with you.
Can CION give this treatment?
Immunotherapy is given at CION centres, and the tumour board reviews your scans before any plan is confirmed. Scans and endoscopy are arranged through accredited partners. Call the helpline, and a medical oncologist will go through your reports with you.
Your Specialists
Meet CION's liver cancer specialists. Bring your scan reports and liver blood tests.
Our medical and surgical oncologists plan liver cancer care together, weighing the tumour and how well your liver works before choosing surgery, a liver-directed procedure or medicines.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Sources
- American Cancer Society — Immunotherapy for Liver Cancer
- EASL — EASL Clinical Practice Guidelines: management of hepatocellular carcinoma
- National Cancer Institute — Liver Cancer Treatment
- American Cancer Society — Treatment of Liver Cancer, by Stage
This page is general information, not a prescription. Do not change or stop any treatment based on what you read here. If anything is worrying you, contact your own treating team — or call our helpline and we will help you reach the right specialist.
Keep reading
Related pages
Atezolizumab plus bevacizumab for liver cancerThe other first-choice combination, compared in detailImmunotherapy alone for liver cancerWhen a single immune drug is used instead of a pairWhy Child-Pugh decides what treatment you can haveThe liver test behind every drug decisionSecond-line treatment after first-line failsWhat comes next if the first treatment stops working
Talk to us
Has your doctor mentioned durvalumab plus tremelimumab?
Send us your scans, endoscopy and blood reports, and a medical oncologist will explain whether this combination fits your liver and why. One helpline serves every CION centre.